RTR888 (iMG)

About Retro Biosciences

Retro Biosciences is an ambitious, privately-held biotech focused on longevity, aiming to add a decade of healthy human lifespan by targeting the root mechanisms of aging. The company has built a diversified preclinical pipeline centered on four core technology platforms: hematopoietic stem cell (HSC) reprogramming, autophagy enhancement, microglia therapeutics, and in vivo tissue reprogramming. With a team of over 60 and advised by prominent longevity researchers, Retro is pursuing a high-risk, high-reward strategy to translate aging biology into human therapeutics, operating in a capital-intensive, pre-revenue stage.

Therapeutic Areas